Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Buys 245,113 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc acquired 245,113 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were bought at an average cost of $7.86 per share, for a total transaction of $1,926,588.18. Following the completion of the acquisition, the director directly owned 5,175,604 shares of the company’s stock, valued at approximately $40,680,247.44. The trade was a 4.97% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, November 5th, Orbimed Advisors Llc bought 156,091 shares of Electra Therapeutics stock. The stock was purchased at an average cost of $7.31 per share, for a total transaction of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc bought 71,367 shares of Electra Therapeutics stock. The stock was purchased at an average cost of $7.53 per share, for a total transaction of $537,393.51.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The stock was purchased at an average price of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Down 7.8%

Shares of ETRA stock opened at $7.35 on Friday. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Analyst Ratings Changes

Several brokerages have recently issued reports on ETRA. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. HC Wainwright began coverage on Electra Therapeutics in a report on Monday, October 26th. They set a “buy” rating and a $30.00 target price for the company. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Evercore assumed coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, TD Cowen began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $33.50.

Electra Therapeutics News Summary

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, associated with OrbiMed Advisors, reported purchases totaling 472,571 shares across November 3–5, worth approximately $3.6 million. The transactions increased his reported position, a sign of insider confidence. SEC filing
• Neutral Sentiment: Management plans to present at the Jefferies Global Healthcare Conference in London on November 18. The announcement provides an opportunity to discuss the company, but no new clinical or business developments were included. Conference announcement

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.